• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

花生过敏儿童的反应症状及激发剂量与健康相关生活质量的关联

Association of Reaction Symptoms and Eliciting Dose With Health-Related Quality of Life in Children With Peanut Allergy.

作者信息

Hu Alice, Lloyd Melanie, Loke Paxton, Chebar Lozinsky Adriana, O'Sullivan Michael, Quinn Patrick, Gold Michael, Tang Mimi L K

机构信息

Allergy Immunology, Murdoch Children's Research Institute, Parkville, Victoria, Australia; School of Population and Global Health, University of Melbourne, Parkville, Victoria, Australia.

Allergy Immunology, Murdoch Children's Research Institute, Parkville, Victoria, Australia; Centre for Medicine Use and Safety, Monash University, Parkville, Victoria, Australia.

出版信息

J Allergy Clin Immunol Pract. 2023 Oct;11(10):3195-3202.e4. doi: 10.1016/j.jaip.2023.06.063. Epub 2023 Jul 7.

DOI:10.1016/j.jaip.2023.06.063
PMID:37423341
Abstract

BACKGROUND

Food allergy adversely affects the health-related quality of life (HRQoL) of patients. It is unclear whether factors such as the reaction eliciting dose (ED) and the nature of allergic reaction symptoms affect HRQoL.

OBJECTIVE

To explore associations between reaction ED or the nature of allergic symptoms and HRQoL among children with peanut allergy.

METHODS

This study was a secondary analysis of baseline data from the PPOIT-003 randomized trial in 212 children aged 1 to 10 years with challenge-confirmed peanut allergy. Children's past reaction symptoms were collected by clinicians during screening. Associations between variables of interest and parent-reported child-proxy HRQoL were examined by univariable and multivariable linear regression.

RESULTS

Mean age of study participants was 5.9 years; 63.2% were male. Children with a low reaction ED of 80 mg peanut protein had significantly poorer HRQoL (β = -0.81; 95% CI, -1.61 to -0.00; P = .049) compared with children with a high ED of 2,500 mg peanut protein. Gastrointestinal symptoms (β = 0.45; 95% CI, 0.03-0.87; P = .037), lower airway symptoms (β = 0.46; 95% CI, 0.05-0.87; P = .030), multisystem involvement (β = 0.71; 95% CI, 0.25-1.16; P = .003), or anaphylaxis (β = 0.46; 95% CI, 0.04-0.87; P = .031) during a previous reaction were associated with worse HRQoL.

CONCLUSIONS

Peanut-allergic children with a lower allergen reaction threshold experienced a greater negative HRQoL impact compared with children with higher reaction thresholds. In addition, specific past allergic reaction symptoms were associated with comparatively worse HRQoL. Children experiencing these symptoms and those with lower reaction ED require increased clinical support to manage the food allergy and are likely to benefit from interventions that can improve HRQoL.

摘要

背景

食物过敏会对患者的健康相关生活质量(HRQoL)产生不利影响。尚不清楚引发反应的剂量(ED)和过敏反应症状的性质等因素是否会影响HRQoL。

目的

探讨花生过敏儿童的反应ED或过敏症状的性质与HRQoL之间的关联。

方法

本研究是对PPOIT - 003随机试验的基线数据进行的二次分析,该试验纳入了212名1至10岁经激发试验确诊为花生过敏的儿童。临床医生在筛查期间收集了儿童过去的反应症状。通过单变量和多变量线性回归分析了感兴趣的变量与家长报告的儿童代理HRQoL之间的关联。

结果

研究参与者的平均年龄为5.9岁;63.2%为男性。与花生蛋白激发剂量高(2500mg)的儿童相比,激发剂量低(80mg花生蛋白)的儿童的HRQoL显著较差(β = -0.81;95%CI,-1.61至-0.00;P = 0.049)。既往反应期间出现胃肠道症状(β = 0.45;95%CI,0.03 - 0.87;P = 0.037)、下呼吸道症状(β = 0.46;95%CI,0.05 - 0.87;P = 0.030)、多系统受累(β = 0.71;95%CI,0.25 - 1.16;P = 0.003)或过敏反应(β = 0.46;95%CI,0.04 - 0.87;P = 0.031)与较差的HRQoL相关。

结论

与反应阈值较高的儿童相比,过敏原反应阈值较低的花生过敏儿童对HRQoL的负面影响更大。此外,既往特定的过敏反应症状与相对较差的HRQoL相关。经历这些症状的儿童和反应ED较低的儿童需要更多的临床支持来管理食物过敏,并且可能会从能够改善HRQoL的干预措施中受益。

相似文献

1
Association of Reaction Symptoms and Eliciting Dose With Health-Related Quality of Life in Children With Peanut Allergy.花生过敏儿童的反应症状及激发剂量与健康相关生活质量的关联
J Allergy Clin Immunol Pract. 2023 Oct;11(10):3195-3202.e4. doi: 10.1016/j.jaip.2023.06.063. Epub 2023 Jul 7.
2
Peanut Allergen Threshold Study (PATS): Novel single-dose oral food challenge study to validate eliciting doses in children with peanut allergy.花生过敏原阈值研究(PATS):一项新的单剂量口服食物挑战研究,旨在验证花生过敏儿童的激发剂量。
J Allergy Clin Immunol. 2017 May;139(5):1583-1590. doi: 10.1016/j.jaci.2017.01.030. Epub 2017 Feb 24.
3
The Peanut Allergy Burden Study: Impact on the quality of life of patients and caregivers.花生过敏负担研究:对患者及照料者生活质量的影响
World Allergy Organ J. 2021 Feb 15;14(2):100512. doi: 10.1016/j.waojou.2021.100512. eCollection 2021 Feb.
4
Effect of Epicutaneous Immunotherapy vs Placebo on Reaction to Peanut Protein Ingestion Among Children With Peanut Allergy: The PEPITES Randomized Clinical Trial.表皮免疫治疗与安慰剂对花生过敏儿童进食花生蛋白反应的影响:PEPITES 随机临床试验。
JAMA. 2019 Mar 12;321(10):946-955. doi: 10.1001/jama.2019.1113.
5
Modified oral food challenge used with sensitization biomarkers provides more real-life clinical thresholds for peanut allergy.改良的口服食物激发试验结合致敏生物标志物,为花生过敏提供了更符合实际临床情况的阈值。
J Allergy Clin Immunol. 2014 Aug;134(2):390-8. doi: 10.1016/j.jaci.2014.03.035. Epub 2014 May 13.
6
Efficacy and safety of oral immunotherapy with AR101 in European children with a peanut allergy (ARTEMIS): a multicentre, double-blind, randomised, placebo-controlled phase 3 trial.AR101 口服免疫治疗欧洲花生过敏儿童的疗效和安全性(ARTEMIS):一项多中心、双盲、随机、安慰剂对照 3 期试验。
Lancet Child Adolesc Health. 2020 Oct;4(10):728-739. doi: 10.1016/S2352-4642(20)30234-0. Epub 2020 Jul 20.
7
Probiotic peanut oral immunotherapy versus oral immunotherapy and placebo in children with peanut allergy in Australia (PPOIT-003): a multicentre, randomised, phase 2b trial.益生菌花生口服免疫治疗与口服免疫治疗和安慰剂在澳大利亚花生过敏儿童中的比较(PPOIT-003):一项多中心、随机、2b 期试验。
Lancet Child Adolesc Health. 2022 Mar;6(3):171-184. doi: 10.1016/S2352-4642(22)00006-2. Epub 2022 Feb 4.
8
What affects quality of life among caregivers of food-allergic children?食物过敏儿童照顾者的生活质量受哪些因素影响?
Ann Allergy Asthma Immunol. 2014 Jul;113(1):69-74.e2. doi: 10.1016/j.anai.2014.04.016.
9
Study protocol of a multicentre, randomised, controlled trial evaluating the effectiveness of probiotic and peanut oral immunotherapy (PPOIT) in inducing desensitisation or tolerance in children with peanut allergy compared with oral immunotherapy (OIT) alone and with placebo (the PPOIT-003 study).多中心、随机、对照试验研究方案,评估益生菌和花生口服免疫治疗(PPOIT)与单独口服免疫治疗(OIT)和安慰剂相比在诱导花生过敏儿童脱敏或耐受方面的有效性(PPOIT-003 研究)。
BMJ Open. 2020 Sep 9;10(9):e035871. doi: 10.1136/bmjopen-2019-035871.
10
Post hoc analysis examining symptom severity reduction and symptom absence during food challenges in individuals who underwent oral immunotherapy for peanut allergy: results from three trials.对接受花生过敏口服免疫疗法的个体在食物激发试验期间症状严重程度降低和无症状情况的事后分析:三项试验的结果
Allergy Asthma Clin Immunol. 2023 Mar 13;19(1):21. doi: 10.1186/s13223-023-00757-8.